This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Daiichi Sankyo Co., Ltd.

Drug Names(s): DJ-927

Description: Tesetaxel is an orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Tesetaxel was developed to maintain the high antitumor activity of the taxane drug class whileeliminating infusion reactions, reducing neuropathy. Preclinically, tesetaxel hasdemonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.

Deal Structure: Genta and Daiichi
In March 2008, Genta announced it entered into anexclusive worldwide licensing agreement with Daiichi Sankyo for the development and commercialization of tesetaxel. Under terms of the agreement, Daiichi Sankyo will receive upfront payments, payments pursuant to the achievement of certain milestones, androyalties on product sales.

In August 2012, Genta filed a voluntary petition for relief under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Tesetaxel News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug